

REMARKS

Claims 1-40 are currently pending in the present application.

Claims 4, 7, 9, 10, 15, 16, 20 and 28 have been amended to identify sequences recited therein with specific sequence identification numbers. Support for these claim amendments is provided by the originally filed claims and specification.

The specification has been amended to recite a claim of priority to related International and French patent applications in accordance with the originally filed Application Data Sheet.

The specification has been amended to identify sequences listed therein with specific sequence identification numbers. It should be mentioned that the sequences of SEQ ID NOS: 132-142, as described in the originally filed specification, are identical to the sequences of SEQ ID NOS: 33-43, as shown in the originally filed sequence listing, respectively. Accordingly, the sequence identifiers of SEQ ID NOS: 132-142 have been renumbered as SEQ ID NOS: 33-43, respectively.

The specification has also been amended to correct obvious inadvertently introduced typographical errors.

Support for the amendment to the sequence of SEQ ID NO: 4 at page 14, line 21, claim 15 at page 37, line 12, and the original sequence listing, is found at specification page 15, line 10, page 23, line 2, page 28, Table 1, page 31, line 2, and claim 15 at page 37, line 20.

Support for the amendment to the sequence of SEQ ID NO: 5 at page 15, line 22, and page 23, line 14, is found at specification page 14, line 21, page 28, Table 1, page 31, line 9, claim 15 at page 37, line 13, and the original sequence listing.

Support for the amendment to the sequence of SEQ ID NO: 9 at page 14, line 1, is found at specification page 22, line 10, and the original sequence listing.

Support for the amendment to the sequence of SEQ ID NO: 41 at page 33, Table 3, is found at specification page 12, line 13, claim 7 at page 36, line 7, and the original sequence listing.

The specification has further been amended to replace the previously submitted Sequence Listing with the attached substitute Sequence Listing. In response to the Notice to Comply with Requirements, Applicants append herewith a printed (pdf.file) copy of a written substitute Sequence Listing along with a corresponding electronic (txt.file) copy of the substitute Sequence Listing recorded in computer readable form. Applicants submit that the content of the electronic copy of the substitute Sequence Listing is identical to the printed copy of the written substitute Sequence Listing. Applicants further submit that the sequence shown in the electronically filed substitute Sequence Listing is identical to the sequence contained in this application as originally filed. Support for the sequence listed in the printed, and corresponding electronic, substitute Sequence Listing is found within the present application as originally filed.


It is believed that no new matter has been introduced by the amendments to the claims, specification, and the submission of the attached substitute Sequence Listing.

In view of the foregoing, Applicants respectfully submit that the present application is now in compliance with 37 C.F.R. §§ 1.821-1.825. Therefore, withdrawal of the Notice to Comply with Requirements is respectfully requested.

Applicants submit that the present application is in condition for examination on the merits, and early examination of claims 1-40 is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



David P. Stitzel
Attorney of Record
Registration No. 44,360

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 06/04)